BioAscent Discovery will manage Medivir AB’s compound collection of approximately 56,000 samples, on an outsourced basis. In addition to the existing collection of protease inhibitors and nucleoside analogues, new compounds are being synthesized and delivered to BioAscent each week from Medivir’s CRO partner in India. BioAscent integrates these new compounds into the existing collection and prepares master stock solutions for Medivir drug discovery activities. Medivir scientists order compounds on a weekly basis and BioAscent supplies them in ready to be tested formats. 
 
BioAscent’s Newhouse facility offers scalable and secure infrastructure, capable of managing solid and liquid compounds, in numerous tube and microplate formats, from ambient to -20 °C. BioAscent is also processing and despatching compounds to Medivir research partners in Europe, the U.S., and Asia.
 
Dr. Sylviane Boucharens, BioAscent’s chief operating officer, said, “The BioAscent team is highly experienced at planning the transfer process in meticulous detail, and the Medivir and BioAscent teams combined well to ensure that there was little or no downtime.” 
 
Mr. Paul Smith, chief executive officer, BioAscent, said, “The number of companies outsourcing the management of their compound libraries to BioAscent continues to grow apace and we are very pleased to be managing Medivir’s expanding library. Our purpose-built facility near Edinburgh, Scotland is designed for both small and large collections, and we expect to have more announcements in the near future. This continued growth and trust in BioAscent’s world–class facility in Scotland is the perfect platform from which to build our new range of complementary drug discovery services.”